1 October 2024 false No description of principal activity Taxfiler 2024.6 true 13600022business:PrivateLimitedCompanyLtd2024-10-012025-09-30 136000222024-09-30 136000222024-10-012025-09-30 13600022business:AuditExempt-NoAccountantsReport2024-10-012025-09-30 13600022business:FilletedAccounts2024-10-012025-09-30 136000222025-09-30 13600022business:Director12024-10-012025-09-30 13600022business:Director22024-10-012025-09-30 13600022business:RegisteredOffice2024-10-012025-09-30 136000222024-09-30 13600022core:WithinOneYear2025-09-30 13600022core:WithinOneYear2024-09-30 13600022core:ShareCapitalcore:PreviouslyStatedAmount2025-09-30 13600022core:ShareCapitalcore:PreviouslyStatedAmount2024-09-30 13600022core:SharePremiumcore:PreviouslyStatedAmount2025-09-30 13600022core:SharePremiumcore:PreviouslyStatedAmount2024-09-30 13600022core:CapitalContributionReservecore:PreviouslyStatedAmount2025-09-30 13600022core:CapitalContributionReservecore:PreviouslyStatedAmount2024-09-30 13600022core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-09-30 13600022core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-09-30 13600022core:PreviouslyStatedAmount2025-09-30 13600022core:PreviouslyStatedAmount2024-09-30 13600022business:SmallEntities2024-10-012025-09-30 13600022countries:EnglandWales2024-10-012025-09-30 13600022core:PlantMachinery2024-10-012025-09-30 13600022core:FurnitureFittings2024-10-012025-09-30 13600022core:ComputerEquipment2024-10-012025-09-30 13600022core:IntangibleAssetsOtherThanGoodwill2024-09-30 13600022core:IntangibleAssetsOtherThanGoodwill2024-10-012025-09-30 13600022core:IntangibleAssetsOtherThanGoodwill2025-09-30 13600022core:PlantMachinery2024-09-30 13600022core:FurnitureFittings2024-09-30 13600022core:ComputerEquipment2024-09-30 13600022core:PlantMachinery2025-09-30 13600022core:FurnitureFittings2025-09-30 13600022core:ComputerEquipment2025-09-30 13600022core:DisposalsRepaymentsInvestments2025-09-30 13600022core:BetweenOneFiveYears2025-09-30 13600022core:BetweenOneFiveYears2024-09-30 136000222023-10-012024-09-30 iso4217:GBP xbrli:pure
Company Registration No. 13600022 (England and Wales)
Samphire Neuroscience Ltd Unaudited accounts for the year ended 30 September 2025
Samphire Neuroscience Ltd Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Samphire Neuroscience Ltd Company Information for the year ended 30 September 2025
Directors
Alexander Cook Emile Radyte
Company Number
13600022 (England and Wales)
Registered Office
85 Great Portland Street First Floor London W1W 7LT England
Accountants
Your Cloud Accountant Limited The Keep Creech Castle Taunton Somerset TA1 2DX
- 3 -
Samphire Neuroscience Ltd Statement of financial position as at 30 September 2025
2025 
2024 
Notes
£ 
£ 
Fixed assets
Intangible assets
4
71,498 
- 
Tangible assets
5
7,740 
18,120 
Investments
6
- 
2,187 
79,238 
20,307 
Current assets
Inventories
49,953 
87,305 
Debtors
7
132,765 
11,385 
Cash at bank and in hand
943,205 
551,454 
1,125,923 
650,144 
Creditors: amounts falling due within one year
8
(41,808)
(67,224)
Net current assets
1,084,115 
582,920 
Net assets
1,163,353 
603,227 
Capital and reserves
Called up share capital
154 
154 
Share premium
1,661,081 
1,661,081 
Capital contribution reserve
10
1,618,795 
- 
Profit and loss account
(2,116,677)
(1,058,008)
Shareholders' funds
1,163,353 
603,227 
For the year ending 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 30 April 2026 and were signed on its behalf by
Alexander Cook Director Company Registration No. 13600022
- 4 -
Samphire Neuroscience Ltd Notes to the Accounts for the year ended 30 September 2025
1
Statutory information
Samphire Neuroscience Ltd is a private company, limited by shares, registered in England and Wales, registration number 13600022. The registered office is 85 Great Portland Street, First Floor, London, W1W 7LT, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Going concern
The company was in a period of product development prior to the current financial year. It has started to generate sales and has a strong balance sheet. It relies on grant income and the support of its shareholders and is currently able to meet its liabilities as they fall due. The shareholders have no intention of withdrawing their support for the foreseeable future. For this reason, the directors consider it appropriate to prepare the financial statements on a going concern basis.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
50% cost
Fixtures & fittings
50% cost
Computer equipment
50% cost
Stocks and work in progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work‑in‑progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
Research and development expenditure
Expenditure on research and development is written off in the year in which it is incurred. Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstated. Development costs are amortised on a straight line basis over their useful life once the related project is complete and available for use.
- 5 -
Samphire Neuroscience Ltd Notes to the Accounts for the year ended 30 September 2025
Foreign exchange
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
Pension costs
The company operates a defined contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.
Government grants
Government grants are recognised in the profit and loss account in an appropriate manner that matches them with the expenditure towards which they are intended to contribute. Grants for immediate financial support or to cover costs already incurred are recognised immediately in the profit and loss account. Grants towards general activities of the entity over a specific period are recognised in the profit and loss account over that period. Grants towards fixed assets are recognised over the expected useful lives of the related assets and are treated as deferred income and released to the profit and loss account over the useful life of the asset concerned. All grants in the profit and loss account are recognised when all conditions for receipt have been complied with. Grants also include Research & Development Expenditure Credits received.
Change of accounting estimate
During the period the directors assessed the relevance of the useful lives that had been applied to fixed assets historically. It was agreed that a policy of 2 years was appropriate and in line with the technical nature of the company. All assets are now depreciated over 2 years straight line compared to the original methods of: Plant & machinery - 20% cost Fixtures & fittings - 25%
cost Computer equipment - 25%
cost
4
Intangible fixed assets
Other 
£ 
Cost
At 1 October 2024
- 
Additions
71,498 
At 30 September 2025
71,498 
Amortisation
At 1 October 2024
- 
At 30 September 2025
- 
Net book value
At 30 September 2025
71,498 
Intangibles represents development costs.
- 6 -
Samphire Neuroscience Ltd Notes to the Accounts for the year ended 30 September 2025
5
Tangible fixed assets
Plant & machinery 
Fixtures & fittings 
Computer equipment 
Total 
£ 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At cost 
At 1 October 2024
7,749 
3,586 
12,794 
24,129 
Additions
- 
- 
8,219 
8,219 
Disposals
- 
(3,586)
(12,794)
(16,380)
At 30 September 2025
7,749 
- 
8,219 
15,968 
Depreciation
At 1 October 2024
241 
1,666 
4,102 
6,009 
Charge for the year
4,499 
897 
6,250 
11,646 
On disposals
- 
(2,563)
(6,864)
(9,427)
At 30 September 2025
4,740 
- 
3,488 
8,228 
Net book value
At 30 September 2025
3,009 
- 
4,731 
7,740 
At 30 September 2024
7,508 
1,920 
8,692 
18,120 
6
Investments
Subsidiary undertakings 
£ 
Valuation at 1 October 2024
2,187 
Disposals
(2,187)
Valuation at 30 September 2025
- 
During the year the 100% subsidiary was dissolved.
7
Debtors
2025 
2024 
£ 
£ 
Amounts falling due within one year
VAT
15,939 
6,316 
Trade debtors
1,240 
- 
Accrued income and prepayments
49,861 
5,069 
Other debtors
65,725 
- 
132,765 
11,385 
- 7 -
Samphire Neuroscience Ltd Notes to the Accounts for the year ended 30 September 2025
8
Creditors: amounts falling due within one year
2025 
2024 
£ 
£ 
Bank loans and overdrafts
- 
1,882 
Trade creditors
23,778 
1,721 
Taxes and social security
300 
12,492 
Other creditors
7,830 
- 
Accruals
9,900 
- 
Deferred income
- 
51,129 
41,808 
67,224 
Deferred tax assets have not been accounted for on taxable losses carried forward due to the uncertainty of taxable profits.
10
Capital contribution reserve
This represents capital injections from the parent that have not been converted into shares.
11
Operating lease commitments
2025 
2024 
£ 
£ 
At 30 September 2025 the company had the following future minimum lease payments under non-cancellable operating leases for each of the following periods:
Not later than one year
118,800 
29,081 
Later than one year and not later than five years
69,300 
- 
188,100 
29,081 
12
Transactions with related parties
[PLACEHOLDER FOR SHARE OPTIONS]
13
Controlling party
The ultimate parent is Samphire Group Inc, a US company registered in 1209 Orange Street, New Castle County, Wilmington, Delaware, 1980.
14
Average number of employees
During the year the average number of employees was 7 (2024: 6).
- 8 -